eligibility_summary
Inclusion: Adults ≥18, ECOG ≤2, consented RRMM with t(11,14) and measurable disease, ≥1 prior line including PI, IMiD, and anti‑CD38 with progression, prior ASCT ≥100 d OK, adequate marrow, liver, renal (eGFR ≥30), calcium, contraception, AEs ≤Grade 1. Exclusion: prior venetoclax/anti‑BCMA, recent therapy/plasmapheresis/radiation/surgery, corneal disease, unstable hepatic/renal/GI/cardiac disease, HIV/HBV/HCV, allo SCT, amyloidosis/POEMS/PCL, CNS MM, pregnancy, live vaccines, CYP3A modifiers/grapefruit, other trials.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/IIa trial in relapsed/refractory t(11,14) multiple myeloma testing belantamab mafodotin plus venetoclax, ± dexamethasone. Belantamab mafodotin: antibody-drug conjugate (humanized anti-BCMA mAb linked to MMAF). Mechanism: binds BCMA on malignant plasma cells, internalizes, releases MMAF to disrupt microtubules and induce apoptosis, Fc effector function may add ADCC/ADCP. Venetoclax: oral small-molecule BCL-2 inhibitor that triggers mitochondrial apoptosis, especially active in t(11,14) MM with BCL-2 dependence. Dexamethasone: glucocorticoid that enhances cytotoxic/apoptotic effects. Targets: BCMA-expressing plasma cells and the BCL-2 anti-apoptotic pathway.